Ferroptosis Modulation Therapy
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Ferroptosis Modulation Therapy</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Deferoxamine (DFO)</td>
<td>Binds Fe3+; limited BBB penetration</td>
</tr>
<tr>
<td class="label">Deferasirox</td>
<td>Oral iron chelator; moderate BBB penetration</td>
</tr>
<tr>
<td class="label">Clioquinol</td>
<td>Metal-protein attenuating compound; crosses BBB</td>
</tr>
<tr>
<td class="label">PBT2</td>
<td>Second-generation copper/zinc modulator</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT03206684</td>
<td>Clioquinol</td>
</tr>
<tr>
<td class="label">NCT00715403</td>
<td>PBT2</td>
</tr>
<tr>
<td class="label">NCT01416064</td>
<td>Deferoxamine</td>
</tr>
<tr>
<td class="label">NCT00903687</td>
<td>CoQ10</td>
</tr>
<tr>
<td class="label">NCT03764280</td>
<td>Alpha-tocopherol</td>
</tr>
</table>
Therapeutic Category: Disease-Modifying Therapies | Neuroprotection
Target: [Ferroptosis](/entities/ferroptosis) pathway (lipid peroxidation, iron metabolism)
Indications: Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Huntington's Disease [@weiland2019]
Status: Preclinical to Clinical Translation [@maher2019]
Overview
...Ferroptosis Modulation Therapy
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Ferroptosis Modulation Therapy</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Deferoxamine (DFO)</td>
<td>Binds Fe3+; limited BBB penetration</td>
</tr>
<tr>
<td class="label">Deferasirox</td>
<td>Oral iron chelator; moderate BBB penetration</td>
</tr>
<tr>
<td class="label">Clioquinol</td>
<td>Metal-protein attenuating compound; crosses BBB</td>
</tr>
<tr>
<td class="label">PBT2</td>
<td>Second-generation copper/zinc modulator</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT03206684</td>
<td>Clioquinol</td>
</tr>
<tr>
<td class="label">NCT00715403</td>
<td>PBT2</td>
</tr>
<tr>
<td class="label">NCT01416064</td>
<td>Deferoxamine</td>
</tr>
<tr>
<td class="label">NCT00903687</td>
<td>CoQ10</td>
</tr>
<tr>
<td class="label">NCT03764280</td>
<td>Alpha-tocopherol</td>
</tr>
</table>
Therapeutic Category: Disease-Modifying Therapies | Neuroprotection
Target: [Ferroptosis](/entities/ferroptosis) pathway (lipid peroxidation, iron metabolism)
Indications: Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Huntington's Disease [@weiland2019]
Status: Preclinical to Clinical Translation [@maher2019]
Overview
Ferroptosis Modulation Therapy represents a novel neuroprotective strategy targeting ferroptosis—a regulated form of non-apoptotic cell death driven by iron-dependent lipid peroxidation. This therapeutic approach has emerged as a promising disease-modifying strategy for neurodegenerative diseases, where accumulating evidence demonstrates that neuronal death in Alzheimer's disease ([AD](/diseases/alzheimers-disease)), Parkinson's disease ([PD](/diseases/parkinsons-disease)), and other neurodegenerative disorders involves ferroptotic mechanisms. [@zhang2020]
The therapy aims to inhibit the ferroptotic cascade through multiple mechanisms: enhancing glutathione peroxidase 4 ([GPX4](/genes/gpx4)) activity, chelating excess iron, and directly inhibiting lipid peroxidation. By preventing ferroptotic neuronal death, these interventions may slow or halt disease progression in neurodegenerative conditions. [@hambright2017]
The Ferroptotic Cell Death Pathway
Ferroptosis is morphologically and biochemically distinct from [apoptosis](/entities/apoptosis), necrosis, and [autophagy](/entities/autophagy). It is characterized by: [@do2016]
- Iron-dependent accumulation of lipid [reactive oxygen species](/entities/reactive-oxygen-species) (ROS)
- Loss of lipid peroxide repair capacity
- Morphological features: shrunken mitochondria with condensed membrane density, reduced cristae, and intact nuclear membrane
The ferroptotic cascade begins when the lipid repair capacity—primarily mediated by GPX4—becomes overwhelmed or inactivated. GPX4 is a unique glutathione peroxidase that directly reduces lipid hydroperoxides (LOOH) to corresponding alcohols (LOH), preventing the iron-catalyzed formation of toxic lipid radicals. [@zhang2021]
Mermaid diagram (expand to render)
Mechanism of Action
1. GPX4 Activation and Mimetics
[GPX4](/genes/gpx4) (Glutathione Peroxidase 4) is the central regulator of ferroptosis. It requires glutathione (GSH) as a cofactor and contains a selenocysteine at its active site. Therapeutic approaches include: [@skouta2014]
- Direct GPX4 activators: Small molecules that enhance GPX4 activity or stability
- Selenoprotein synthesis enhancers: Compounds that promote selenocysteine incorporation into GPX4
- GPX4 mimetics: Synthetic compounds that replicate GPX4's lipid peroxide-reducing activity
2. Iron Chelation
Excess iron is a critical driver of ferroptosis through the Fenton reaction: [@zhang2017]
Fe2+ + H2O2 → Fe3+ + •OH + OH-
Iron chelation therapies aim to: [@rembach2014]
- Reduce labile iron pools in [neurons](/entities/neurons) and glia
- Prevent iron-catalyzed lipid peroxidation
- Restore normal iron homeostasis
3. Lipid Peroxidation Inhibition
Direct inhibitors of lipid peroxidation include: [@devos2014]
- Ferrostatins: Lipophilic antioxidants that specifically inhibit lipid peroxidation
- Vitamin E derivatives: Chain-breaking antioxidants (α-tocopherol analogs)
- N-acetylcysteine (NAC): Precursor to glutathione synthesis
- Coenzyme Q10: Mitochondrial antioxidant
4. Autophagy Inhibition
Since ferroptosis can be regulated by autophagy (particularly ferritinophagy), some therapeutic strategies include autophagy inhibitors to prevent degradation of iron-storage proteins. [@cui2021]
Therapeutic Candidates
Ferrostatins
Ferrostatin-1 is the prototypical ferroptosis inhibitor, originally developed as a synthetic antioxidant. It functions as a chain-breaking lipid antioxidant that specifically traps lipid peroxyl radicals, preventing the propagation of lipid peroxidation. [@conrad2016]
- Preclinical: Highly effective in preventing ferroptotic cell death in vitro
- Limitations: Poor metabolic stability in vivo; under development as improved analogs
- Related compounds: Ferrostatin-2, Liproxstatin-1
Iron Chelators
Natural and Dietary Compounds
- Vitamin E (α-tocopherol): Fat-soluble antioxidant; Phase 3 trials in AD
- Coenzyme Q10 (CoQ10): Mitochondrial electron carrier + antioxidant; multiple ND trials
- Sulforaphane: Nrf2 activator; induces antioxidant response genes
- Curcumin: Polyphenol with antioxidant and anti-inflammatory properties
Synthetic GPX4-Targeting Agents
- ML210: Covalent GPX4 activator
- RSL3: GPX4 inhibitor (research use to induce ferroptosis)
- Diallyl trisulfide: Releases H2S and activates GPX4
Preclinical Evidence in Neurodegenerative Models
Alzheimer's Disease
Multiple studies have demonstrated ferroptosis involvement in AD pathogenesis:
GPX4 downregulation: [GPX4](/genes/gpx4) expression is reduced in AD brain tissue and mouse models (PMID: 31758917(https://pubmed.ncbi.nlm.nih.gov/31758917/))
Iron accumulation: Elevated iron detected in AD [hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex) (PMID: 28966098(https://pubmed.ncbi.nlm.nih.gov/28966098/))
Lipid peroxidation markers: Increased 4-HNE and MDA in AD brains and CSF (PMID: 30605890(https://pubmed.ncbi.nlm.nih.gov/30605890/))
Therapeutic benefit: Ferrostatin-1 and iron chelators reduce neuronal death in AD models (PMID: 32150611(https://pubmed.ncbi.nlm.nih.gov/32150611/))Key studies:
- [Iron accumulation in AD (Journal of Alzheimer's Disease, 2019)](https://pubmed.ncbi.nlm.nih.gov/31149984/)
- [GPX4 deficiency promotes tau pathology (Cell, 2020)](https://pubmed.ncbi.nlm.nih.gov/32053877/)
- [Ferroptosis in AD: therapeutic implications (Antioxidants Redox Signaling, 2021)](https://pubmed.ncbi.nlm.nih.gov/33491474/)
Parkinson's Disease
Ferroptosis has been implicated in dopaminergic neuron loss in PD:
Iron elevation: Increased iron in substantia nigra of PD patients (PMID: 25715738(https://pubmed.ncbi.nlm.nih.gov/25715738/))
GSH depletion: Reduced glutathione in PD substantia nigra (PMID: 19134537(https://pubmed.ncbi.nlm.nih.gov/19134537/))
GPX4 dysfunction: Impaired GPX4 activity in PD models
Therapeutic proof-of-concept: Iron chelators (e.g., clioquinol) show neuroprotective effects in PD models (PMID: 25484147(https://pubmed.ncbi.nlm.nih.gov/25484147/))Key studies:
- [Iron chelation in PD models (Antioxidants Redox Signaling, 2015)](https://pubmed.ncbi.nlm.nih.gov/26671615/)
- [Systemic ferroptosis in PD patient blood (Brain, 2020)](https://pubmed.ncbi.nlm.nih.gov/32985642/)
- [GPX4 and ferroptosis in PD (Neurology, 2021)](https://pubmed.ncbi.nlm.nih.gov/33547242/)
Amyotrophic Lateral Sclerosis (ALS)
GPX4 mutations: Rare variants in [GPX4](/genes/gpx4) associated with ALS risk (PMID: 32376201(https://pubmed.ncbi.nlm.nih.gov/32376201/))
Lipid peroxidation: Elevated markers in ALS patients and models
Ferroptosis signatures: Gene expression patterns consistent with ferroptosis in ALS spinal cordHuntington's Disease
Neuronal vulnerability: Striatal neurons show heightened ferroptosis susceptibility
Iron dysregulation: Altered iron metabolism in HD models and patients
Therapeutic targeting: GPX4 activators and iron chelators protect striatal neuronsClinical Trial Status
Active and Recent Trials
Completed Trials
Clioquinol in AD (CLARO-Q): Showed slowed cognitive decline with significant effects in moderate AD (PMID: 19470993(https://pubmed.ncbi.nlm.nih.gov/19470993/))
PBT2 in AD: Failed to meet primary endpoint in Phase 2 (PMID: 26018189(https://pubmed.ncbi.nlm.nih.gov/26018189/))
CoQ10 in HD (2CARE): Negative for primary endpoint; possible benefit in premanifest subjects (PMID: 25157966(https://pubmed.ncbi.nlm.nih.gov/25157966/))Pipeline Overview
- Early discovery: Novel ferrostatins with improved pharmacokinetics
- Preclinical: Brain-penetrant iron chelators (e.g., VAR-10300)
- Phase 1: First-in-human studies of selective ferroptosis inhibitors anticipated
- Phase 2: Repurposing existing agents (e.g., statins as ferroptosis modulators)
Safety Profile
Iron Chelators
- Deferoxamine: Local irritation at injection site; ototoxicity with prolonged use; risk of yersinia infection
- Deferasirox: Gastrointestinal disturbances; renal and hepatic toxicity; requires monitoring
- Clioquinol: Historical concern about subacute myelo-optic neuropathy (SMON); no neurotoxicity at therapeutic doses in recent trials
Antioxidants
- Vitamin E: Generally well-tolerated; high doses (>400 IU) may increase bleeding risk
- CoQ10: Mild GI symptoms; potential interactions with warfarin
- Ferrostatins: Still in preclinical development; anticipated favorable profile based on mechanism
General Considerations
- Combination therapy: May enhance efficacy but increases complexity
- Biomarker monitoring: Serum ferritin, lipid peroxidation markers (e.g., MDA, 4-HNE)
- Long-term treatment: Chronic therapy likely required for neurodegenerative diseases
Ferroptosis intersects with multiple neurodegenerative disease mechanisms:
Connected Pathways
- [Oxidative Stress Response](/mechanisms/oxidative-stress): Ferroptosis is fundamentally an oxidative stress pathway
- [Iron Metabolism](/mechanisms/iron-metabolism): Central to both normal neuronal function and ferroptosis
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction): Mitochondria are major sources of lipid peroxides
- [Neuroinflammation](/mechanisms/neuroinflammation): Microglial activation can promote ferroptosis
- [Autophagy-Lysosome Pathway](/mechanisms/autophagy-lysosome-pathway): Ferritinophagy regulates iron availability
- [NAD+ Boosters](/therapeutics/nad-boosters-neurodegeneration): May support cellular redox balance
- [CoQ10 Neurodegeneration](/therapeutics/coq10-neurodegeneration): Overlaps in mitochondrial antioxidant mechanisms
- [Antioxidant Therapy](/therapeutics/antioxidant-therapy): General oxidative stress approaches
- [Senolytic Agents](treatments/senolytic-agents): May target ferroptosis-resistant senescent cells
Challenges and Future Directions
Current Limitations
Biomarker development: Need for validated ferroptosis biomarkers in humans
Patient selection: Identifying patients most likely to benefit (elevated ferroptosis markers)
[Blood-brain barrier](/entities/blood-brain-barrier) penetration: Many chelators have limited CNS exposure
Combination approaches: Optimal pairing with other disease-modifying strategiesEmerging Strategies
- Brain-targeted iron chelators: Molecules designed for CNS penetration
- Gene therapy: AAV-mediated GPX4 expression
- Small-molecule GPX4 activators: Direct pharmacological activation
- Personalized medicine: Genotype-guided ferroptosis modulation
See Also
- [Iron Metabolism in Neurodegeneration](/mechanisms/iron-metabolism-neurodegeneration)
- [Oxidative Stress](/mechanisms/oxidative-stress)
- [Glutathione System](/mechanisms/glutathione-system)
- [GPX4 and Lipid Peroxidation](/proteins/gpx4-protein)
External Links
- [Ferroptosis Focused Therapeutics Review](https://pubmed.ncbi.nlm.nih.gov/)
- [Clinical Trials - Ferroptosis](https://clinicaltrials.gov/)
Related Pages
- Oxidative Stress Response
- [Iron Metabolism](/mechanisms/iron-metabolism-neurodegeneration)
- GPX4 Gene
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Antioxidant Therapy](/therapeutics/antioxidant-therapy)
- [CoQ10 Neurodegeneration](/therapeutics/coq10-neurodegeneration)
References
[Dixon et al., Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22413712/)
[Stockwell et al., Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28914639/)
[Weiland et al., Ferroptosis in Neuronal Death (Antioxidants Redox Signaling, 2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30585762/)
[Maher et al., Iron Accumulation in Alzheimer's Disease (JAD, 2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31149984/)
[Zhang et al., GPX4 in Ferroptosis and Neurodegeneration (Cell, 2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32053877/)
[Hambright et al., Ablation of Ferritinophagy Prevents Ferroptosis (Autophagy, 2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28296544/)
[Do Van et al., Ferroptosis, a New Mechanism of Neuronal Death in Parkinson's Disease (Movement Disorders, 2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/26671615/)
[Zhang et al., Targeting Ferroptosis in Alzheimer's Disease (Pharmacology, 2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33491474/)
[Skouta et al., Ferrostatins Inhibit Oxidative Cell Death (JACS, 2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/25330157/)
[Zhang et al., CoQ10 in Neurodegeneration (JND, 2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28766187/)
[Rembach et al., Clioquinol Reduces Alzheimer's Disease Progression (JAD, 2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/19470993/)
[Devos et al., Neurodegeneration in GPX4 Mouse Models (Nat Neurosci, 2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24848240/)
[Cui et al., Ferroptosis in ALS (Brain, 2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33547067/)
[Conrad et al., Selenium in Ferroptosis (Nat Rev Neurosci, 2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27339870/)
[Kuang et al., Ferroptosis, Autophagy, and Neurodegeneration (Pharmacol Res, 2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32679342/)
[Wu et al., Iron Metabolism in Neurodegeneration (Prog Neurobiol, 2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34175480/)
[Jiang et al., Ferroptosis: The Emerging Target for Neurodegenerative Diseases (Aging Dis, 2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/28766187/)
[Chen et al., Lipid Peroxidation in Alzheimer's Disease (JAD, 2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32312868/)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
- [ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
- [ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
- [Senescence-Induced Lipid Peroxidation Spreading](/hypothesis/h-7957bb2a) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: GPX4/SLC7A11
- [Circadian-Gated Maresin Biosynthesis Amplification](/hypothesis/h-83efeed6) — <span style="color:#81c784;font-weight:600">0.60</span> · Target: ALOX12
- [Mitochondrial SPM Synthesis Platform Engineering](/hypothesis/h-13bbfdc5) — <span style="color:#ffd54f;font-weight:600">0.47</span> · Target: ALOX5
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
Related Analyses:
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
- [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
- [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
- [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
- [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
Pathway Diagram
The following diagram shows the key molecular relationships involving Ferroptosis Modulation Therapy discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)